Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis.

Ghaddar HM, Folsom AR, Aleksic N, Hearne LB, Chambless LE, Morrissey JH, Wu KK.

Circulation. 1998 Dec 22-29;98(25):2815-21.

PMID:
9860781
2.

Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.

Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH.

Leuk Lymphoma. 1996 Jun;22(1-2):71-6.

PMID:
8724530
3.

Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.

Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O'Brien S, Keating MJ, Freireich EJ, Estey EH.

Leukemia. 1996 Jun;10(6):964-9.

PMID:
8667653
4.

A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.

Raad II, Whimbey EE, Rolston KV, Abi-Said D, Hachem RY, Pandya RG, Ghaddar HM, Karl CL, Bodey GP.

Cancer. 1996 Apr 1;77(7):1386-94.

PMID:
8608520
5.
7.

Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH.

Leukemia. 1994 Aug;8(8):1269-74.

PMID:
8057660

Supplemental Content

Loading ...
Support Center